SEC Form 4 · accession 0000784199-17-000009
ARTIVION, INC. · AORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott B Capps
Officer — VP, Clinical Research
Period of report
Feb 19, 2017
Accepted (ET)
Feb 22, 2017 · 6:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000784199
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 19, 2017 | F | 1,747 | $17.25 | D | 107,366 | D | |
| Common StockF2 | Feb 19, 2017 | A | 10,471 | $17.25 | A | 109,113 | D | |
| Common StockF1 | Feb 19, 2017 | F | 785 | $17.25 | D | 98,642 | D | |
| Common StockF3 | Feb 21, 2017 | A | 4,444 | $0.00 | A | 111,810 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $16.30 | holding | — | — | — | Feb 21, 2018 | Feb 21, 2024 | Common Stock | 12,520 | 12,520 | D |
Explanation of responses
- F1These shares were withheld upon the vesting of restricted stock to pay tax withholding obligations.
- F2Represents performance stock units granted on February 19, 2016 and earned at approximately 142.2% of target based on 2016 adjusted EBITDA. Fifty percent (50%) were issued on February 19, 2017. The remaining shares earned in connection with the February 2016 grant will vest and be issued as follows: 50% on 02/19/2018, and 50% on 02/19/2019, assuming continued employment on the relevant vesting date.
- F3Represents share of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company.